Summed up with a few errors...pd1Vax is not yet in Ph 2 trial,...

Summed up with a few errors...
pd1Vax is not yet in Ph 2 trial, the Ph1 is likely to start in next few months, not in India, Asia or Eastern Europe but in Australia and USA.

Cf33 results will be a lot earlier than next year, due to enroll August, but investigators will be able to see within 10 days tumors being exploded . Study is across multiple cancer types. Safety and tolerability usually is reported at 2_3months.

If any of these treatments can extend life for a large percentage of those diagnosed as terminal out to 6, 12, 24 months that is a massive shift in life expectancy from Terminal. And consequently annual sales of Us$5billion easily achievable per product, based on comparisons to current succesful checkpoint inhibitors. Do the maths on that...
And here we are today with a market cap still below US$100 million. With very little downside to trade but significant upside of 10 to 20 times from here it is hard to fathom how anyone who understands the story could have a Sell Sentiment and Not Held position. Look at other immuno-oncology buy outs.... nothing inked in millions, they're all deals in billions.
Read between the lines of the noise, find clues to be very optimistic.... and despite Corona and a large fund liquidating their entire position, realise we're actually doing pretty well and the shareprice is still trading at a massive big discount to what might otherwise be the case.